282 related articles for article (PubMed ID: 36053302)
1. [The gut-liver axis: how the gut promotes liver disease].
Demir M; Tacke F
Inn Med (Heidelb); 2022 Oct; 63(10):1028-1035. PubMed ID: 36053302
[TBL] [Abstract][Full Text] [Related]
2. Gut-liver axis-mediated mechanism of liver cancer: A special focus on the role of gut microbiota.
Ohtani N; Hara E
Cancer Sci; 2021 Nov; 112(11):4433-4443. PubMed ID: 34533882
[TBL] [Abstract][Full Text] [Related]
3. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
Albillos A; de Gottardi A; Rescigno M
J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
[TBL] [Abstract][Full Text] [Related]
4. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Arab JP; Martin-Mateos RM; Shah VH
Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
[TBL] [Abstract][Full Text] [Related]
5. Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites.
Ding Y; Yanagi K; Cheng C; Alaniz RC; Lee K; Jayaraman A
Pharmacol Res; 2019 Mar; 141():521-529. PubMed ID: 30660825
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.
Arab JP; Arrese M; Shah VH
Hepatol Res; 2020 Apr; 50(4):407-418. PubMed ID: 31840358
[TBL] [Abstract][Full Text] [Related]
7. New strain of
Jiang XW; Li YT; Ye JZ; Lv LX; Yang LY; Bian XY; Wu WR; Wu JJ; Shi D; Wang Q; Fang DQ; Wang KC; Wang QQ; Lu YM; Xie JJ; Li LJ
World J Gastroenterol; 2020 Oct; 26(40):6224-6240. PubMed ID: 33177795
[TBL] [Abstract][Full Text] [Related]
8. The role of the gut microbiota in NAFLD.
Leung C; Rivera L; Furness JB; Angus PW
Nat Rev Gastroenterol Hepatol; 2016 Jul; 13(7):412-25. PubMed ID: 27273168
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiome as a therapeutic target for liver diseases.
Singh TP; Kadyan S; Devi H; Park G; Nagpal R
Life Sci; 2023 Jun; 322():121685. PubMed ID: 37044173
[TBL] [Abstract][Full Text] [Related]
10. The Gut-Liver Axis in Health and Disease: The Role of Gut Microbiota-Derived Signals in Liver Injury and Regeneration.
Zheng Z; Wang B
Front Immunol; 2021; 12():775526. PubMed ID: 34956204
[TBL] [Abstract][Full Text] [Related]
11. Deciphering the role of gut metabolites in non-alcoholic fatty liver disease.
Ralli T; Saifi Z; Tyagi N; Vidyadhari A; Aeri V; Kohli K
Crit Rev Microbiol; 2023 Nov; 49(6):815-833. PubMed ID: 36394607
[TBL] [Abstract][Full Text] [Related]
12. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
[TBL] [Abstract][Full Text] [Related]
13. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.
de Faria Ghetti F; Oliveira DG; de Oliveira JM; de Castro Ferreira LEVV; Cesar DE; Moreira APB
Eur J Nutr; 2018 Apr; 57(3):861-876. PubMed ID: 28875318
[TBL] [Abstract][Full Text] [Related]
14. Microbiome-liver crosstalk: A multihit therapeutic target for liver disease.
Kirundi J; Moghadamrad S; Urbaniak C
World J Gastroenterol; 2023 Mar; 29(11):1651-1668. PubMed ID: 37077519
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiome and nonalcoholic fatty liver disease.
Wu MY; Fan JG
Hepatobiliary Pancreat Dis Int; 2023 Oct; 22(5):444-451. PubMed ID: 37308360
[TBL] [Abstract][Full Text] [Related]
16. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.
Lang S; Schnabl B
Cell Host Microbe; 2020 Aug; 28(2):233-244. PubMed ID: 32791115
[TBL] [Abstract][Full Text] [Related]
17. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
Chu H; Duan Y; Yang L; Schnabl B
Gut; 2019 Feb; 68(2):359-370. PubMed ID: 30171065
[TBL] [Abstract][Full Text] [Related]
18. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease.
Aragonès G; González-García S; Aguilar C; Richart C; Auguet T
Biomed Res Int; 2019; 2019():8507583. PubMed ID: 30719448
[TBL] [Abstract][Full Text] [Related]
19. Gut-liver axis in the progression of nonalcoholic fatty liver disease: From the microbial derivatives-centered perspective.
Luo L; Chang Y; Sheng L
Life Sci; 2023 May; 321():121614. PubMed ID: 36965522
[TBL] [Abstract][Full Text] [Related]
20. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement.
Ji Y; Yin Y; Sun L; Zhang W
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
